Oncompass Medicine

Oncompass Medicine is a Hungarian medical enterprise that develops decision support and diagnostic medical software for personalized cancer treatment. Its proprietary AI software uses identified gene defects to determine molecular targets and matching targeted compounds, and it is offered within a Precision Oncology Program covering lung, prostate, ovarian, melanoma and gastric cancers.

The program includes online and in-person consultations and a virtual molecular tumor board, where clinical oncologists, geneticists, molecular pharmacologists and laboratory specialists discuss each case before and after molecular examinations. The service is aimed at oncology teams and their cancer patients, and the company describes its role as professional support for therapists and oncology teams. The software is further developed by Genomate Health Inc., a Boston-based biotechnology company founded by István Petak and Oncompass Medicine.

The company was founded in 2003 and is headquartered in Budapest. Its partnerships include a 2022 role with BC Platforms and Euformatics in delivering standardized oncology NGS workflows to seven European hospitals, and 2023 Eurostars funding with Euformatics and Institut Curie for an oncology solution with genomic noise canceling. The careers page invites applications to a talent pool for software, data, science, medicine and business roles.

Product: AI-based decision support software for selecting molecular-based targeted cancer treatments, used within a Precision Oncology Program with virtual tumor board.